A Phase 2 interventional study of PAT-001, 0.1% and PAT-001, 0.2% in Congenital Ichthyosis, sponsored by Patagonia Pharmaceuticals, LLC. Completed at 5 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.
Sponsored by Patagonia Pharmaceuticals, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Congenital ichthyosis (CI) is a large, heterogeneous family of inherited skin disorders of cornification resulting from an abnormality of skin keratinization, such as scaling and thickening of the skin. Treatment options include keratolytic agents, which can abruptly lead to extensive shedding or peeling of scales. PAT-001 primarily acts as a keratolytic agent; thus, making it a potential drug candidate for the treatment of skin disorders associated with hyperkeratinization, such as CI. The current study intends to evaluate the safety and tolerability of PAT-001 in patients with CI of either the Lamellar or X-Linked subtypes.
The management of CI is a life-long endeavor, which remains largely symptomatic (i.e., emollients with or without keratolytics agents) and commonly focused on reducing scaling and/or skin lubrication with both systemic and topical treatments. A first-line therapy includes hydration and lubrication accomplished by creams and ointments containing low concentrations of salt, urea, or glycerol, which increase the water-binding capacity of the horny layer. Addition of keratolytics agents are used to decrease corneocyte cohesiveness, to promote desquamation, and to dissolve keratins and lipids (e.g., α-hydroxy acids, salicylic acid, high dose urea, propylene glycol, N-acetylcysteine, and retinoids). Systemic retinoid treatment is reserved for those patients refractory to topical agents because of long-term adverse effects and teratogenicity.
This is a two part, Phase 2, multicenter, proof-of-concept (POC) study of the safety and tolerability of PAT-001 for the treatment of Congenital ichthyosis (CI) in patients ages 12 years of age and older. Part 1 will be a double-blind, randomized, vehicle controlled, bilateral comparison of two treatments (PAT-001 [0.1% or 0.2%] vs. vehicle) for eight (8) weeks.
Part 2 will be a double-blind, active only treatment comparison of the two PAT-001 concentrations (0.1% or 0.2%) for an additional four (4) weeks. Subjects will have the option to participate in the pharmacokinetics (PK) portion of the study.
This is the only study on the registry with Patagonia Pharmaceuticals, LLC as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply only PAT-001, 0.1% to both Treatment Areas from Weeks 8-12.
Drug: PAT-001, 0.1%
Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). This comparison lasts from Weeks 0-8 Part 2: Patients will apply PAT-001, 0.2% to both Treatment Areas.
Drug: PAT-001, 0.2%
Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.1% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
Drug: Vehicle for PAT-001 0.1%
Part 1: Bilateral comparison. Patients will have two comparable Treatment Areas: PAT-001, 0.2% (e.g., left side) and Vehicle, 0.0% (e.g., right side). The application of vehicle only lasts from Weeks 0-8.
Drug: Vehicle for PAT-001 0.2%
PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
Also known as: PAT-001
PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
Also known as: PAT-001
Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.1%.
Also known as: Vehicle
Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001 0.2%.
Also known as: Vehicle
Number of Participants With Adverse Events (AEs) in Part 1 of Trial (Weeks 0-8)
The number of participants with AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.
Time frame: Day 0 through Day 57 (Weeks 0-8)
Incidence of Local Skin Reactions (LSRs) in Participants Treated With PAT-001 0.1%, 0.2% and/or Vehicle
LSRs including burning/stinging, pain, and pruritus (itch) will be assessed in each Treatment Area using a four-point ordinal scale where 0=none, 1=mild, 2=moderate, and 3=severe (based on the investigator's evaluation of the skin reaction) at each clinic visit to allow a comparison between Treatment Groups and Test Articles. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding or reduction in dosing frequency of the test articles will be documented in this LSR Table. Any LSRs that are not listed here will be recorded as AEs.
Time frame: Up to Day 84 (Weeks 0-12)
Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1)
Overall severity of ichthyosis will be graded using a five-point scale Investigator Global Assessment (IGA) based upon a 5 point scale going from 0=clear., 1=almost clear, 2=mild, 3=moderate to 4=severe. Scoring is based upon investigator evaluation. This is a static morphological scale that refers to a point in time and not a comparison to Baseline.
Time frame: Up to Day 57
Number of Participants Achieving an Improvement of at Least 1 Point Score in the Individual Clinical Signs/Symptoms of Erythema, Scaling, Fissuring and Papulation/Lichenification Using a Five-point Scale
Overall severity of erythema (redness), scaling , fissuring (cracks in skin), and papulation/lichenification (skin thickening, increased pigmentation and/or exaggerated skin lines, formation of papules) will be graded using a five-point scale from 0=clear, 1=almost clear, 2=mild, 3=moderate to 4=severe. This is a static morphological scale that refers to a point in time and not a comparison to Baseline. This scoring is based upon investigator discretion.
Time frame: Up to Day 57 (Weeks 0-8)
Pharmacokinetics of PAT-001 0.1% and 0.2% at Different Timepoints
Serum concentrations for PAT-001 0.1% and PAT-001 0.2% looking at blood levels obtained at timepoints outlined
Time frame: Day 1 (0,1, 2, 3, and 4 hours post Dose)
Recruitment: March 8, 2017-February 13, 2018. Recruited at 5 clinics in United States associated with US Universities by practicing dermatologists
| Milestone | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle |
|---|---|---|
| Started | 10 | 9 |
| Completed | 7 | 5 |
| Not completed | 3 | 4 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
The number of participants with AEs will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported.
| participants | Group 1 PAT-001 0.1% | Group 2 PAT-001 0.2% | Group 1 Vehicle | Group 2 Vehicle |
|---|---|---|---|---|
| Number of Subjects with TEAE | 7 | 7 | 5 | 5 |
| Number of Treatment Emergent Adverse Events (TEAE) within treatment area | 4 | 5 | 3 | 3 |
| Number of Deaths due to TEAE | 0 | 0 | 0 | 0 |
| Number of Serious TEAE | 0 | 1 | 0 | 0 |
| Number of Patients who Discontinued in the trial due to TEAE | 1 | 1 | 0 | 0 |
| Number of Patients with Severe TEAE | 1 | 1 | 0 | 0 |
| Number of Patients with Moderate TEAE | 3 | 3 | 2 | 2 |
| Number of Patients with Mild TEAE | 4 | 6 | 3 | 3 |
| Number of Patients Where the TEAE was Considered Definitely Related to Treatment | 1 | 1 | 0 | 0 |
| Number of Patients where the TEAE was Considered Probably Related to Treatment | 1 | 0 | 0 | 0 |
| Number of Patients Where the TEAE was Considered Possibly Related to Treatment | 1 | 4 | 1 | 1 |
| Number of Patients Where the TEAE was Considered Not Related to Treatment | 1 | 5 | 4 | 4 |
LSRs including burning/stinging, pain, and pruritus (itch) will be assessed in each Treatment Area using a four-point ordinal scale where 0=none, 1=mild, 2=moderate, and 3=severe (based on the investigator's evaluation of the skin reaction) at each clinic visit to allow a comparison between Treatment Groups and Test Articles. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding or reduction in dosing frequency of the test articles will be documented in this LSR Table. Any LSRs that are not listed here will be recorded as AEs.
| participants | Group 1 PAT-001 0.1% | Group 1 Vehicle | Group 2 PAT-001 0.2% | Group 2 Vehicle |
|---|---|---|---|---|
| Application site pruritis (severe) | 1 | 0 | 0 | 0 |
| Application site irritation (mild) | 3 | 2 | 0 | 0 |
| Application site dermatitis (moderate) | 0 | 0 | 1 | 0 |
| Application site rash (mild) | 1 | 0 | 0 | 1 |
| Application site reaction (mild) | 0 | 0 | 1 | 0 |
| Application site pain (moderate) | 1 | 0 | 0 | 0 |
| Application site Pruritis (moderate) | 1 | 1 | 0 | 0 |
| Application site Pruritis (mild) | 1 | 1 | 0 | 0 |
| Application site Dermatitis (mild) | 0 | 0 | 1 | 2 |
Overall severity of ichthyosis will be graded using a five-point scale Investigator Global Assessment (IGA) based upon a 5 point scale going from 0=clear., 1=almost clear, 2=mild, 3=moderate to 4=severe. Scoring is based upon investigator evaluation. This is a static morphological scale that refers to a point in time and not a comparison to Baseline.
| Participants | Group 1 PAT-001 0.1% | Group 2 PAT-001 0.2% | Group 1 Vehicle | Group 2 Vehicle |
|---|---|---|---|---|
| Number of Participants Achieving Improvement to State of Clear, Almost Clear or Mild in the Investigator's Global Assessment (IGA) Using a Five-point Scale at Day 57 (Part 1) | 9 | 8 | 6 | 7 |
Overall severity of erythema (redness), scaling , fissuring (cracks in skin), and papulation/lichenification (skin thickening, increased pigmentation and/or exaggerated skin lines, formation of papules) will be graded using a five-point scale from 0=clear, 1=almost clear, 2=mild, 3=moderate to 4=severe. This is a static morphological scale that refers to a point in time and not a comparison to Baseline. This scoring is based upon investigator discretion.
| participants | Group 1 PAT-001 0.1% | Group 2 PAT-001 0.2% | Group 1 Vehicle | Group 2 Vehicle |
|---|---|---|---|---|
| Scaling | 9 | 6 | 7 | 8 |
| Fissuring | 6 | 6 | 5 | 6 |
| Papulation/lichenification | 9 | 6 | 6 | 7 |
| Erythema | 5 | 5 | 4 | 6 |
Serum concentrations for PAT-001 0.1% and PAT-001 0.2% looking at blood levels obtained at timepoints outlined
| ng/mL | Group 1 | Group 2 (Part 1) |
|---|---|---|
| Pre-Dose | 1.495 ± 0.6718 | 2.48 ± 1.795 |
| 1 Hour | 1.5 ± 0.6505 | 2.227 ± 1.3725 |
| 2 Hours | 1.425 ± 0.5303 | 2.12 ± 1.2257 |
| 3 Hours | 1.37 ± 0.297 | 2.063 ± 1.5332 |
| 4 Hours | 1.375 ± 0.0778 | 1.453 ± 0.3625 |
Collected over 84 Days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 PAT-001 0.1% | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Group 2 PAT-001 0.2% | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| Group 1 Vehicle | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Group 2 Vehicle | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Event | Group 1 PAT-001 0.1% | Group 2 PAT-001 0.2% | Group 1 Vehicle | Group 2 Vehicle |
|---|---|---|---|---|
| C. difficile colitisInfections and infestations | 0/10 | 1/9 | 0/10 | 0/9 |
| Novavirus gastroenteritisInfections and infestations | 0/10 | 1/9 | 0/10 | 0/9 |
| mental status changesPsychiatric disorders | 0/10 | 1/9 | 0/10 | 0/9 |
| Event | Group 1 PAT-001 0.1% | Group 2 PAT-001 0.2% | Group 1 Vehicle | Group 2 Vehicle |
|---|---|---|---|---|
| Application site pruritisGeneral disorders | 3/10 | 0/9 | 2/10 | 1/9 |
| Upper Respiratory Tract InfectionInfections and infestations | 0/10 | 2/9 | 0/10 | 0/9 |
| Arthropod biteInjury, poisoning and procedural complications | 2/10 | 0/9 | 0/10 | 0/9 |
| Application site dermatitisSkin and subcutaneous tissue disorders | 2/10 | 0/9 | 0/10 | 0/9 |
| C. difficile colitisInfections and infestations | 0/10 | 1/9 | 0/10 | 0/9 |
| Blood triglycerides increasedInvestigations | 0/10 | 1/9 | 0/10 | 0/9 |
| Mental status changesPsychiatric disorders | 0/10 | 1/9 | 0/10 | 0/9 |
| Gastroenteritis novovirusInfections and infestations | 0/10 | 1/9 | 0/10 | 0/9 |
| Tooth infectionInfections and infestations | 0/10 | 1/9 | 0/10 | 0/9 |
| ContusionInjury, poisoning and procedural complications | 0/10 | 1/9 | 0/10 | 0/9 |
| Age, Continuous(years) | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle | Total |
|---|---|---|---|
| Mean | 37.5 ± 20.3 | 47.2 ± 18.4 | 42 ± 19.3 |
| Sex: Female, Male(Participants) | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle | Total |
|---|---|---|---|
| Female | 5 | 4 | 9 |
| Male | 5 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 10 | 9 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle | Total |
|---|---|---|---|
| United States | 10 | 9 | 19 |
| BMI(kg/m^2) | Group 1 PAT-001 0.1% and Vehicle | Group 2 PAT-001 0.2% and Vehicle | Total |
|---|---|---|---|
| Median | 28.8 (19 to 33.9) | 26.4 (18 to 41.2) | 27.7 (18 to 41.2) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Feb 2018, 11 months.
Results were first posted in Sep 2021, 3 years 6 months after primary completion. A results delay was requested in Jun 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isotretinoin
Ichthyosis Vulgaris